Four years into what is now the longest-running stimulant medication shortage in recent U.S. history, patients are running into a version of this problem they thought was behind them. Late 2025 and early 2026 brought real relief — lower-strength Adderall got easier to find, and the news coverage largely moved on. Then, by June 2026, pharmacies across multiple states were again reporting empty shelves, and the FDA's own shortage database confirmed it: this isn't déjà vu, it's a second wave in a shortage that never actually ended. Here's exactly what changed, why the DEA's quota increases didn't fix it, and what to do if you're the one holding an empty prescription bottle this week.
1. Is Adderall Officially in Shortage?
Unlike some medications where "shortage" is more of a media label than a regulatory fact, Adderall's situation is formally documented. The FDA first posted a nationwide shortage notice for amphetamine mixed salts on October 12, 2022, citing manufacturing delays at Teva Pharmaceutical Industries, the largest domestic producer. That notice remains live today, and the American Society of Health-System Pharmacists (ASHP) independently tracks the same shortage through its own drug shortage database, which lists status updates by individual manufacturer.
What changed in June 2026: The FDA's shortage listing showed multiple companies again reporting "limited" or "no availability" status for some or all Adderall doses, including Alvogen, Aurobindo Pharma, Epic Pharma, Granules Pharmaceuticals, Lannett Company, Oryza Pharmaceuticals, Sandoz, SpecGx, and Teva. Companies cited different reasons — some pointed to increased demand, others to active ingredient sourcing constraints — but the practical result for patients was the same regardless of the paperwork reason: empty shelves.
The distinction between "on the FDA list" and "out of stock at your specific pharmacy" still matters. A drug can appear on the shortage list while some pharmacies, especially those in lower-demand areas or with strong wholesaler relationships, still have stock. The reverse is also true — a drug can occasionally sell out locally even when national supply looks reasonable. Calling ahead beats assuming either way.
2. Why It's "Back": The 2026 Reversal
This is the part that confuses most patients, and reasonably so: if the DEA raised production limits, why did things get worse again?
In October 2025, the DEA raised the aggregate production quota for d-amphetamine from 21.2 million grams to 26.5 million grams — a 25% increase, and the first major quota adjustment since the shortage began. Further increases were finalized in January 2026. Through the first two months of 2026, this translated into real improvement: lower-dose tablets (5 mg, 10 mg) became noticeably easier to find, though 15 mg, 25 mg, and 30 mg extended-release capsules stayed constrained, with manufacturer resupply estimates repeatedly slipping.
A federal production quota sets the ceiling on how much amphetamine active ingredient can be manufactured nationally in a given year. It does not guarantee that every individual manufacturer will actually produce, package, and ship their allotted share on schedule. That gap is exactly what played out by mid-2026: several generic manufacturers hit their own company-specific constraints — some in raw ingredient sourcing, some in production or packaging capacity — independent of the higher national ceiling. At the same time, demand kept climbing as ADHD diagnosis and treatment rates continued to rise nationally, which meant even a 25% larger supply pool didn't fully catch up to what pharmacies needed to keep shelves stocked.
In short: the quota increase raised the speed limit, but several manufacturers still couldn't drive that fast, and the number of cars on the road kept growing too.
3. Timeline: Four Years of Adderall Shortage
| Date | Event |
|---|---|
| Oct 12, 2022 | FDA formally declares an Adderall shortage after manufacturing delays at Teva, the largest U.S. producer |
| 2023 | Shortage spreads across nearly all manufacturers of amphetamine mixed salts, both IR and XR formulations |
| Aug 2023 | FDA shortage listing updated as backorders persist across multiple dosage strengths |
| June 2024 | CDC issues a Health Advisory warning that disrupted stimulant access could push patients toward unsafe, unregulated alternatives, including counterfeit pills |
| 2025 (mid-year) | Supply pressure continues; adult-dose strengths remain hardest to source nationally |
| Oct 2025 | DEA raises d-amphetamine production quota 25%, from 21.2M to 26.5M grams — the first major quota increase since 2022 |
| Jan 2026 | DEA finalizes further quota increases for the 2026 production year |
| Feb 2026 | Low-dose availability (5 mg, 10 mg) improves; 15-30 mg XR strengths remain constrained, with manufacturer estimates extending to late February and beyond |
| June 4, 2026 | Multiple generic manufacturers again report limited-or-no availability to the FDA; some estimate recovery as far out as October 2026 or January 2027 |
| July 2026 | FDA and ASHP shortage listings remain active; brand Adderall IR from Teva reported available in many regions |
4. Current Availability by Strength
Availability in a national shortage is never uniform across every dose. Adderall's shortage has consistently hit adult-typical strengths hardest, since those are the doses prescribed most often and therefore the ones pharmacies burn through fastest.
| Formulation & Strength | Typical Status |
|---|---|
| Adderall IR 5 mg, 10 mg | Generally easier to locate |
| Adderall IR 20 mg, 30 mg | Most consistently constrained |
| Adderall XR 5 mg, 10 mg | Improved since early 2026 |
| Adderall XR 15 mg, 20 mg, 25 mg, 30 mg | Frequently back-ordered |
| Brand Adderall IR (Teva) | Reported available in many regions |
5. Manufacturer Status: Who Has What
Because Adderall and its generics are produced by many different companies, "the shortage" is really a patchwork of individual manufacturer statuses that shift week to week. As of the June 2026 FDA shortage update, manufacturer-reported timelines varied widely:
| Manufacturer | Reported Status | Estimated Recovery |
|---|---|---|
| Teva Pharmaceuticals | Brand Adderall IR available | Ongoing |
| Alvogen | Limited availability | 5-10 days (self-reported) |
| Lannett Company | Limited availability | End of June 2026 (self-reported) |
| Sandoz Inc. | Limited availability | End of June 2026 (self-reported) |
| Aurobindo Pharma | Limited/no availability | October 2026 (self-reported) |
| Granules Pharmaceuticals | Limited/no availability | October 2026 (self-reported) |
| Oryza Pharmaceuticals | Limited/no availability | January 2027 (self-reported) |
These are manufacturer self-reported estimates filed with the FDA, and shortage recovery dates in this class of drug have slipped before — sometimes repeatedly. Treat any single date as a planning reference, not a guarantee, and don't schedule a refill around a specific month without also having a backup plan.
6. Alternatives: What's Actually in Stock
If your usual Adderall product isn't available, there are two broad categories of alternatives: other products in the same amphetamine class, and products in a different stimulant class entirely (methylphenidate-based) or non-stimulant medications. None of these are automatic pharmacy substitutions the way a generic swap for a non-controlled drug might be — a new prescription is required to change products, and often to change strength or formulation too.
| Alternative | Class | Key consideration |
|---|---|---|
| Mydayis | Amphetamine (extended-release) | Longer duration of action than Adderall XR; different release profile |
| Evekeo | Amphetamine (immediate-release) | Different salt composition; typically dosed more frequently |
| Dexedrine / dextroamphetamine | Amphetamine (single-isomer) | Contains only one of the two amphetamine isomers in Adderall; dosing isn't a direct 1:1 swap |
| Vyvanse (lisdexamfetamine) | Amphetamine prodrug | Inactive until metabolized in the body; smoother onset/offset for many patients, once-daily dosing |
| Concerta / methylphenidate ER | Methylphenidate | Different active ingredient entirely; some patients respond better to one class than the other |
| Focalin (dexmethylphenidate) | Methylphenidate | Single-isomer methylphenidate; separate dosing conventions from Adderall |
| Strattera (atomoxetine) / Qelbree (viloxazine) | Non-stimulant | Not a controlled substance; takes weeks to reach full effect, so not useful for an immediate gap |
Staying in the amphetamine class
- Similar mechanism to what you're already taking, which may mean a more predictable response
- Vyvanse in particular has its own, largely separate supply chain from Adderall's generic manufacturers
- Often a smaller adjustment for prescribers to reason through than a full class change
Switching to methylphenidate
- Different active ingredient means response and side effects can differ meaningfully between patients
- May require a fresh trial-and-error period on dosing
- Its own supply has occasionally been affected too, so check current availability before assuming it's a safe fallback
7. Switching Stimulants Safely
Adderall is a Schedule II controlled substance, which means the rules around switching, transferring, or refilling it are stricter than for most medications. Prescriptions generally can't be called or faxed in by the pharmacy without specific exceptions, can't be transferred between pharmacies the way many non-controlled prescriptions can, and typically can't be refilled early even by a few days without documentation. A prescriber has to write a new prescription for a different product, strength, or class — there's no pharmacist-level substitution the way there might be for, say, a generic statin.
Practically, this means the timeline for switching runs through your prescriber's office, not just your pharmacy counter. Reach out before you're down to your last few doses, since same-day appointments for a controlled-substance change aren't always available, and some practices require an in-person or telehealth visit rather than a message through a patient portal.
8. Step-by-Step: What to Do If You're Turned Away
Call ahead, 5-7 days before you need a refill
Waiting until the day you're out removes your options. Calling nearly a week ahead gives you time to try other pharmacies or reach your prescriber if there's a problem.
Ask specifically about a partial fill
Federal law permits partial fills of Schedule II prescriptions, as long as the total quantity across all partial fills doesn't exceed what was originally prescribed. A pharmacy with some stock, just not a full 30-day supply, may be able to give you a partial amount now and the rest once more arrives.
Check independent pharmacies, not just major chains
Independent pharmacies sometimes carry different generic manufacturers than large chains, and stock levels can vary significantly even within the same chain by location.
Contact your prescriber's office proactively
Let them know your product is unavailable before you run out completely, so there's time to consider a different strength, formulation, or product class rather than making that decision the day you're out of medication.
Confirm insurance coverage before filling an alternative
Ask your insurer whether the alternative product requires prior authorization or step therapy, and whether a shortage-related exception applies. Formularies for stimulants have been updated repeatedly since 2022, so don't assume your plan's rules haven't changed.
Don't stop abruptly to "wait it out"
Abruptly losing stimulant access can cause fatigue, low mood, appetite changes, and difficulty concentrating — recognized discontinuation effects, not a sign of addiction. The CDC's June 2024 Health Advisory specifically flagged this risk and the danger of patients seeking unregulated substitutes. Talk to your prescriber about a bridge plan rather than going without.
9. Cost & Insurance Considerations
Manufacturer copay cards are less common for Schedule II stimulants than for many other drug classes, largely due to controlled-substance program restrictions, so don't expect the kind of $25-$35 manufacturer coupon you might see for a non-controlled brand-name drug. Discount cards like Inside Rx or SingleCare can still meaningfully lower the cash price on generic amphetamine salts, particularly if you're paying out of pocket while your insurance sorts out coverage for an alternative product. If cost is a barrier regardless of which product you end up on, a broader look at prescription assistance programs or understanding how patient assistance programs work is worth the time, even though eligibility for controlled substances is often narrower than for other drug classes. Patients on Medicare should also check how a stimulant switch interacts with current Part D rules, and whether patient assistance options apply to Medicare enrollees in their specific situation.
10. Decision Tree: What Should You Do Right Now?
Ask about a bridge strategy or an alternative product. Don't ration doses or stop abruptly, and don't seek stimulants from unverified sources.
Related: 12 Programs That Help Pay for Prescriptions (2026)
If cost is part of what's pushing you toward a less-available generic, this is worth reading before you switch.